--- title: "Novo Nordisk (NVO) Rethinks Pricing as Compounded GLP-1 Drugs Gain Ground" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/272307926.md" description: "Novo Nordisk CEO Mike Doustdar announced that 1.5 million people in the U.S. are using compounded GLP-1 weight-loss drugs, which are cheaper alternatives to brand-name options like Wegovy. He emphasized that price, not safety, drives this trend. In response, Novo launched a daily oral version of Wegovy at $149 per month. Doustdar noted the need to rethink pricing strategies due to the rise of compounded drugs. Analysts have a Moderate Buy consensus on NVO stock, with an average price target of $54.67, indicating an 8.1% downside risk." datetime: "2026-01-12T18:28:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/272307926.md) - [en](https://longbridge.com/en/news/272307926.md) - [zh-HK](https://longbridge.com/zh-HK/news/272307926.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/272307926.md) | [English](https://longbridge.com/en/news/272307926.md) # Novo Nordisk (NVO) Rethinks Pricing as Compounded GLP-1 Drugs Gain Ground Novo Nordisk (NVO) CEO Mike Doustdar said that as many as 1.5 million people in the U.S. may now be using compounded versions of popular GLP-1 weight-loss drugs. Speaking at the J.P. Morgan Healthcare Conference, he explained that these compounding pharmacies moved faster than big drug companies in understanding what consumers wanted. Because of that, they were able to reach people who could not afford or did not want to pay for expensive brand-name drugs like Wegovy. ### Claim 70% Off TipRanks Premium - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential At the same time, Novo has repeatedly warned that compounded and knock-off GLP-1 drugs can be risky, especially those sold online and marketed directly to consumers. Still, Doustdar said that the main reason people turn to these products is price, not safety. Many compounded versions cost around $199 per month, while branded GLP-1 drugs can cost several hundred dollars without insurance. To respond, Novo recently launched a daily oral version of Wegovy in the U.S. with a starting cash price of $149 per month for those without insurance coverage. Doustdar also said that Novo supports legitimate online pharmacies and telehealth providers, but is actively fighting sellers of counterfeit products that avoid proper FDA oversight. He added that the rapid growth of compounded GLP-1 drugs has been an important lesson for the company by pushing it to rethink how it prices and makes its obesity treatments available going forward. ## **Is NVO Stock a Good Buy?** Turning to Wall Street, analysts have a Moderate Buy consensus rating on NVO stock based on four Buys, three Holds, and one Sell assigned in the past three months, as indicated by the graphic below. Furthermore, the average NVO price target of $54.67 per share implies 8.1% downside risk. ### 相關股票 - [Novo Nordisk AS (NVO.US)](https://longbridge.com/zh-HK/quote/NVO.US.md) ## 相關資訊與研究 - [Novo Nordisk Launches Discounted Subscription Program for Wegovy Obesity Drugs -- Update](https://longbridge.com/zh-HK/news/281201382.md) - [NHS clears Wegovy to reduce risk of heart attack and stroke](https://longbridge.com/zh-HK/news/281323250.md) - [Lexaria Launches New Human Trial to Advance Oral GLP-1 Drug Delivery Platform](https://longbridge.com/zh-HK/news/281413171.md) - [](https://longbridge.com/zh-HK/news/281216333.md) - [Fosun Pharmaceutical's Subsidiary Gets Nod for Phase I Trial for Breast Cancer Drug](https://longbridge.com/zh-HK/news/281480931.md)